La Trobe

Dystrophin S3059 phosphorylation partially attenuates denervation atrophy in mouse tibialis anterior muscles

Download (8.47 MB)
journal contribution
posted on 2024-07-23, 06:00 authored by Kristy Swiderski, Timur Naim, Jennifer Trieu, Annabel Chee, Marco HeroldMarco Herold, Andrew J Kueh, Craig A Goodman, Paul Gregorevic, Gordon S Lynch
The dystrophin protein has well-characterized roles in force transmission and maintaining membrane integrity during muscle contraction. Studies have reported decreased expression of dystrophin in atrophying muscles during wasting conditions, and that restoration of dystrophin can attenuate atrophy, suggesting a role in maintaining muscle mass. Phosphorylation of S3059 within the cysteine-rich region of dystrophin enhances binding between dystrophin and β-dystroglycan, and mimicking phosphorylation at this site by site-directed mutagenesis attenuates myotube atrophy in vitro. To determine whether dystrophin phosphorylation can attenuate muscle wasting in vivo, CRISPR-Cas9 was used to generate mice with whole body mutations of S3059 to either alanine (DmdS3059A) or glutamate (DmdS3059E), to mimic a loss of, or constitutive phosphorylation of S3059, on all endogenous dystrophin isoforms, respectively. Sciatic nerve transection was performed on these mice to determine whether phosphorylation of dystrophin S3059 could attenuate denervation atrophy. At 14 days post denervation, atrophy of tibialis anterior (TA) but not gastrocnemius or soleus muscles, was partially attenuated in DmdS3059E mice relative to WT mice. Attenuation of atrophy was associated with increased expression of β-dystroglycan in TA muscles of DmdS3059E mice. Dystrophin S3059 phosphorylation can partially attenuate denervation-induced atrophy, but may have more significant impact in less severe modes of muscle wasting.

Funding

This study was supported by the National Health and Medical Research Council of Australia (GRNT1144772). The author/s acknowledge the facilities, and the scientific and technical assistance of The Melbourne Advanced Genome Editing Centre (MAGEC). MAGEC is supported by Phenomics Australia (PA). PA is supported by the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) program.

History

Publication Date

2024-07-12

Journal

Physiological Reports

Volume

12

Issue

13

Article Number

e16145

Pagination

15p.

Publisher

Wiley

ISSN

2051-817X

Rights Statement

© 2024 The Author(s). Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Usage metrics

    Journal Articles

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC